Capricor Therapeutics annual operating margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Capricor Therapeutics's operating margin was −191.12% for fiscal 2024.
View full Capricor Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −191.12% | −95.49 pp |
| 2023 | 2023-12-31 | −95.63% | +1068.30 pp |
| 2022 | 2022-12-31 | −1,163.93% | +7385.93 pp |
| 2021 | 2021-12-31 | −8,549.86% | −4137.30 pp |
| 2020 | 2020-12-31 | −4,412.56% | −3643.04 pp |
| 2019 | 2019-12-31 | −769.52% | +147.53 pp |
| 2018 | 2018-12-31 | −917.04% | −434.65 pp |
| 2017 | 2017-12-31 | −482.40% | −57.84 pp |
| 2016 | 2016-12-31 | −424.56% | −195.99 pp |
| 2015 | 2015-12-31 | −228.57% | −102.85 pp |
| 2014 | 2014-12-31 | −125.72% | +1245.99 pp |
| 2013 | 2013-12-31 | −1,371.71% | −297.52 pp |
| 2012 | 2012-12-31 | −1,074.19% | −712.49 pp |
| 2011 | 2011-12-31 | −361.70% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −69.15% | −58.55 pp |
| Q3 2024 | 2024-09-30 | −575.24% | −464.27 pp |
| Q2 2024 | 2024-06-30 | −291.86% | −94.10 pp |
| Q1 2024 | 2024-03-31 | −209.21% | +64.82 pp |
| Q4 2023 | 2023-12-31 | −10.60% | +396.41 pp |
| Q3 2023 | 2023-09-30 | −110.97% | +2003.15 pp |
| Q2 2023 | 2023-06-30 | −197.76% | +2292.99 pp |
| Q1 2023 | 2023-03-31 | −274.04% | +12370.73 pp |
| Q3 2022 | 2022-09-30 | −407.00% | +6822.01 pp |
| Q3 2021 | 2021-09-30 | −2,114.12% | +21096.91 pp |
| Q2 2021 | 2021-06-30 | −2,490.75% | +4503.97 pp |
| Q1 2021 | 2021-03-31 | −12,644.77% | −11509.82 pp |
| Q4 2020 | 2020-12-31 | −7,229.02% | −6561.13 pp |
| Q3 2020 | 2020-09-30 | −23,211.04% | −22065.37 pp |
| Q2 2020 | 2020-06-30 | −6,994.72% | −6491.32 pp |
| Q1 2020 | 2020-03-31 | −1,134.94% | −25.56 pp |
| Q4 2019 | 2019-12-31 | −667.88% | −157.77 pp |
| Q3 2019 | 2019-09-30 | −1,145.67% | +757.16 pp |
| Q2 2019 | 2019-06-30 | −503.39% | +527.16 pp |
| Q1 2019 | 2019-03-31 | −1,109.38% | −187.99 pp |
| Q4 2018 | 2018-12-31 | −510.12% | −227.17 pp |
| Q3 2018 | 2018-09-30 | −1,902.83% | −1060.83 pp |
| Q2 2018 | 2018-06-30 | −1,030.55% | +49.34 pp |
| Q1 2018 | 2018-03-31 | −921.39% | −516.59 pp |
| Q4 2017 | 2017-12-31 | −282.94% | +38.29 pp |
| Q3 2017 | 2017-09-30 | −842.00% | −140.31 pp |
| Q2 2017 | 2017-06-30 | −1,079.89% | −671.65 pp |
| Q1 2017 | 2017-03-31 | −404.81% | −58.27 pp |
| Q4 2016 | 2016-12-31 | −321.23% | −28.82 pp |
| Q3 2016 | 2016-09-30 | −701.69% | −484.90 pp |
| Q2 2016 | 2016-06-30 | −408.24% | −171.18 pp |
| Q1 2016 | 2016-03-31 | −346.54% | −155.55 pp |
| Q4 2015 | 2015-12-31 | −292.41% | −159.23 pp |
| Q3 2015 | 2015-09-30 | −216.79% | −102.68 pp |
| Q2 2015 | 2015-06-30 | −237.07% | −94.94 pp |
| Q1 2015 | 2015-03-31 | −190.99% | −77.19 pp |
| Q4 2014 | 2014-12-31 | −133.18% | +1724.37 pp |
| Q3 2014 | 2014-09-30 | −114.11% | +738.14 pp |
| Q2 2014 | 2014-06-30 | −142.12% | +471.83 pp |
| Q1 2014 | 2014-03-31 | −113.80% | +280.00 pp |
| Q3 2013 | 2013-09-30 | −1,857.54% | −1715.31 pp |
| Q2 2013 | 2013-06-30 | −852.25% | −597.85 pp |
| Q1 2013 | 2013-03-31 | −613.95% | — |
| Q1 2012 | 2012-03-31 | −393.80% | — |
| Q3 2011 | 2011-09-30 | −142.23% | — |
| Q2 2011 | 2011-06-30 | −254.40% | — |
Over the last five reported fiscal years, Capricor Therapeutics's operating margin increased from −769.52% to −191.12%, a change of +578.40 percentage points. The latest reported quarter, Q4 2024, shows −69.15%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Capricor Therapeutics filings at SEC.gov ↗